Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

被引：0
|
作者：
Fatemeh Karimi [1 ]
Mojtaba Aghaei [2 ]
Najmaldin Saki [1 ]
机构：
[1] Ahvaz Jundishapur University of Medical Sciences,
[2] Thalassemia & Hemoglobinopathy Research Center,undefined
[3] Health Research Institute,undefined
[4] Ahvaz Jundishapur University of Medical Sciences,undefined
来源：
Current Treatment Options in Oncology | 2025年 / 26卷 / 3期
关键词：
Polymorphisms; Treatment outcomes; Multiple Myeloma; Genetic markers; Personalized therapy; Biomarkers;
D O I：
10.1007/s11864-025-01295-8
中图分类号：
学科分类号：
摘要：
Multiple myeloma (MM) is a lymphoproliferative disorder that remains a fatal disease despite therapeutic advances.Treatment responses vary among MM patients due to biological factors, tumor characteristics, and genetic differences.Research indicates that genetic polymorphisms, particularly single nucleotide polymorphisms, may influence treatment efficacy and patient outcomes in MM.Ongoing research into these genetic factors may provide valuable insights into the underlying mechanisms of drug efficacy and resistance in this complex disease.
引用
下载
收藏
页码：197 / 212
页数：15
相关论文
共 50 条
  • [41] Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
    S K Kumar
    M A Dimopoulos
    E Kastritis
    E Terpos
    H Nahi
    H Goldschmidt
    J Hillengass
    X Leleu
    M Beksac
    M Alsina
    A Oriol
    M Cavo
    E M Ocio
    M V Mateos
    E K O'Donnell
    R Vij
    H M Lokhorst
    N W C J van de Donk
    C Min
    T Mark
    I Turesson
    M Hansson
    H Ludwig
    S Jagannath
    M Delforge
    C Kyriakou
    P Hari
    U Mellqvist
    S Z Usmani
    D Dytfeld
    A Z Badros
    P Moreau
    K Kim
    P R Otero
    J H Lee
    C Shustik
    D Waller
    W J Chng
    S Ozaki
    J-J Lee
    J de la Rubia
    H S Eom
    L Rosinol
    J J Lahuerta
    A Sureda
    J S Kim
    B G M Durie
    Leukemia, 2017, 31 : 2443 - 2448
  • [42] Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials
    Das, Avash
    Dasgupta, Subhajit
    Gong, Yan
    Shah, Urvi A.
    Fradley, Michael G.
    Cheng, Richard K.
    Roy, Bhaskar
    Guha, Avirup
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) : 233 - 242
  • [43] Immunomodulatory drugs as a therapy for multiple myeloma
    De Raeve, H.
    Vanderkerken, K.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (06) : 415 - 421
  • [44] Mechanism of immunomodulatory drugs in multiple myeloma
    Sedlarikova, Lenka
    Kubiczkova, Lenka
    Sevcikova, Sabina
    Hajek, Roman
    LEUKEMIA RESEARCH, 2012, 36 (10) : 1218 - 1224
  • [45] Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
    Raza, Shahzad
    Safyan, Rachael A.
    Lentzsch, Suzanne
    CURRENT CANCER DRUG TARGETS, 2017, 17 (09) : 846 - 857
  • [46] The role of immunomodulatory drugs in multiple myeloma
    Anderson, KC
    SEMINARS IN HEMATOLOGY, 2003, 40 (04) : 23 - 32
  • [47] Novel proteasome inhibitors in multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (05): : 370 - 372
  • [48] WHEN TO USE NOVEL PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
    Gay, F.
    HAEMATOLOGICA, 2018, 103 : 7 - 7
  • [49] PROTEASOME INHIBITORS FOR USE IN MULTIPLE MYELOMA
    Jain, S.
    Satija, N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2014, 5 (02): : 320 - 329
  • [50] The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
    Paul, Barry
    Zhao, Yue
    Loitsch, Gavin
    Feinberg, Daniel
    Mathews, Parker
    Barak, Ian
    Dupuis, Megan
    Li, Zhiguo
    Rein, Lindsay
    Wang, Endi
    Kang, Yubin
    CANCER MEDICINE, 2020, 9 (16): : 5869 - 5880
12345